scholarly journals Influence of gastric bypass surgery on resting energy expenditure, body composition, physical activity, and thyroid hormones in morbidly obese patients

2018 ◽  
Vol Volume 11 ◽  
pp. 667-672 ◽  
Author(s):  
Mehri Mirahmadian ◽  
Motahareh Hasani ◽  
Ehsaneh Taheri ◽  
Mostafa Qorbani ◽  
Saeed Hosseini
Keyword(s):  
Physical Activity ◽  
Gastric Bypass ◽  
Body Composition ◽  
Energy Expenditure ◽  
Thyroid Hormones ◽  
Bypass Surgery ◽  
Gastric Bypass Surgery ◽  
Resting Energy Expenditure ◽  
Morbidly Obese ◽  
Obese Patients

Predictors of psychological symptoms in morbidly obese patients after gastric bypass surgery

2012 ◽  
Vol 8 (6) ◽  
pp. 770-776 ◽  
Author(s):  
Joaquin Ortega ◽  
Regina Fernandez-Canet ◽  
Sagrario Álvarez-Valdeita ◽  
Norberto Cassinello ◽  
Maria Jose Baguena-Puigcerver
Keyword(s):  
Gastric Bypass ◽  
Bypass Surgery ◽  
Psychological Symptoms ◽  
Gastric Bypass Surgery ◽  
Morbidly Obese ◽  
Obese Patients

Body Composition And Leptin Resistance Following Roux-en-y Gastric Bypass Surgery In Morbidly Obese Females

2011 ◽  
Vol 43 (Suppl 1) ◽  
pp. 102-103
Author(s):  
Jeffrey E. Herrick ◽  
Robert L. Franco ◽  
Jennifer K. Stewart ◽  
James W. Maher ◽  
John M. Kellum ◽  
...  
Keyword(s):  
Gastric Bypass ◽  
Body Composition ◽  
Bypass Surgery ◽  
Gastric Bypass Surgery ◽  
Leptin Resistance ◽  
Morbidly Obese

scholarly journals Roux-en-Y-Bariatric Surgery Reduces Markers of Metabolic Syndrome in Morbidly Obese Patients

2019 ◽  
Vol 30 (2) ◽  
pp. 391-400 ◽  
Author(s):  
G. Rega-Kaun ◽  
C. Kaun ◽  
G. Jaegersberger ◽  
M. Prager ◽  
M. Hackl ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Metabolic Syndrome ◽  
Gastric Bypass ◽  
Bypass Surgery ◽  
Gastric Bypass Surgery ◽  
Morbidly Obese ◽  
Diabetic Patients ◽  
Obese Patients ◽  
C Peptide ◽  
Hepatic Insulin Clearance

Abstract Background Obesity is closely linked to increased markers of metabolic syndrome and development of diabetes. Roux-en-Y bariatric surgery reduces hyperinsulinemia and improves insulin sensitivity and hence benefits morbidly obese patients. Aim To determine changes in markers of metabolic syndrome, pancreatic function, and hepatic insulin sensitivity in patients before and 1 year after undergoing Roux-en-Y gastric bypass surgery. Methods We enrolled 43 consecutive patients in a single center. Markers for metabolic syndrome included proinsulin, insulin, C-peptide, liver enzymes, and serum levels of selected microRNAs hsa-miR-122, hsa-miR-130, hsa-miR-132, and hsa-miR-375. Results After surgery, all patients showed a significant 37% drop of body mass index (p < 0.001). Furthermore, proinsulin (59% reduction, p < 0.001), insulin (76% reduction, p < 0.001), and C-peptide (56% reduction, p < 0.001) were all reduced 1 year after surgery. Using the hepatic insulin clearance score, we determined a significant increase in hepatic insulin clearance after surgery (76% increase, p < 0.001). Especially diabetic patients showed a marked 2.1-fold increase after surgery. Hepatic enzymes ALT (35% reduction, p = 0.002) and γGT (48% reduction, p < 0.001) were significantly reduced in all patients with similar improvement in diabetic and non-diabetic patients. miRNAs hsa-miR-122, hsa-miR-130, and hsa-miR-132 were all significantly reduced whereas hsa-miR-375 was increased after gastric bypass surgery (p < 0.001 for all miRNAs). Conclusion Both liver and pancreatic stress parameters were reduced significantly 1 year after Roux-en-Y gastric bypass surgery suggesting an overall amelioration of the metabolic syndrome in all patients regardless of previous health status.

scholarly journals Association of Circulating Irisin Concentrations with Weight Loss after Roux-en-Y Gastric Bypass Surgery

2019 ◽  
Vol 16 (4) ◽  
pp. 660 ◽  
Author(s):  
Yeon Lee ◽  
Yoonseok Heo ◽  
Ji-Ho Choi ◽  
Sunghyouk Park ◽  
Kyoung Kim ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Gastric Bypass ◽  
Bypass Surgery ◽  
Excess Weight Loss ◽  
Gastric Bypass Surgery ◽  
Morbidly Obese ◽  
Obese Patients ◽  
Preoperative Serum ◽  
One Year

Irisin is a myokine with potential anti-obesity properties that has been suggested to increase energy expenditure in obese patients. However, there is limited clinical information on the biology of irisin in humans, especially in morbidly obese patients undergoing bariatric surgery. We aimed to assess the association of circulating irisin concentrations with weight loss in obese patients undergoing bariatric surgery. This was a pilot, single-centre, longitudinal observational study. We recruited 25 morbidly obese subjects who underwent Roux-en-Y gastric bypass surgery (RYGBP), and blood samples from 12 patients were taken to measure serum irisin concentrations before, and one and nine months after surgery. Their clinical characteristics were measured for one year. The preoperative serum irisin concentration (mean 1.01 ± 0.23 μg/mL, range 0.73–1.49) changed bidirectionally one month after RYGBP. The mean concentration at nine months was 1.11 ± 0.15 μg/mL (range 0.92–1.35). Eight patients had elevated irisin levels compared with their preoperative values, but four did not. Elevations of irisin levels nine months, but not one month, after surgery, were associated with lower preoperative levels (p = 0.016) and worse weight reduction rates (p = 0.006 for the percentage excess weight loss and p = 0.032 for changes in body mass index). The preoperative serum irisin concentrations were significantly correlated with the percentage of excess weight loss for one year (R2 = 0.612; p = 0.04) in our study. Our results suggest that preoperative circulating irisin concentrations may be at least in part associated with a weight loss effect of bariatric surgery in morbidly obese patients. Further large-scale clinical studies are needed to ratify these findings.

Sign in / Sign up

Export Citation Format

Share Document